April 30, 2009

United Health is Ridiculously Cheap

The Fool explains why shares of United Health are "ridiculously cheap." From the article:

"Valuation wise, shares trade at a pitiful 7.3 times forward earnings. Growth has clearly slowed in recent years, but that fact is completely -- if not overly -- baked into the share price."

April 24, 2009

Add Some PB&J to Your Portfolio

The Stock Advisors looks at the J.M. Smucker company in a short article this morning. They argue that the stock is growing and is undervalued as they note that the company just raised their dividend, which they have paid every year since 1960 and has a forward P/E of under 12.

The Fool has also tapped shares of Smucker as an official Inside Value selection.

April 22, 2009

The Future of Dendreon

Seeking Alpha has a lengthy article discussing the future prospects of Dendreon that is primarily being fueled by Provenge, the first cancer drug that will be approved by the FDA. There is tremendous upside for the drug and the stock, but investors should proceed with caution, as the author makes a couple of wild projections as he estimates the future value of the shares.

April 20, 2009

The Future is OLED

A short article at Seeking Alpha looks at Universal Display and their patent portfolio. There is no doubt that OLED technology will fuel growth for the handheld market and that Universal Display should stand to profit. This is still a speculative play and not for the impatient investor, however as no one knows when the "future will be now."

$62 Price Target on Biogen

Zacks reiterates their $62 price target on Biogen in a new article today. In their previous article, Zacks declared that the company had the "best pipeline in Biotech."

Since that time, Biogen released results for the first quarter, where they came in above their bottom line consensus. The company also made the following guidance:

  • Revenues are expected to grow at a rate of high single digits compared to 2008
  • Operating expenses are expected to total $2.0 to $2.1 billion
  • R&D is expected to be 26-28% of revenues, with SG&A at 19-20% of revenues
  • The effective non-GAAP tax rate is expected to be approximately 28-30%
  • Adjusted EPS is expected to be at or above $4.00
  • GAAP EPS is expected to be at or above $2.80

April 15, 2009

Abbott Labs is On Sale

According to the Fool, Abbott Labs is on sale. The stock is currently trading near its 52 week low of $41.88. It is currently trading at 12x this year's earnings and pays a 3.7% dividend.

6.50 Price Target on ZymoGenetics

Zacks has a $6.50 price target on ZymoGenetics, sighting the recent approval of of rhThrombin by the FDA. That is slightly more than double the current price.

April 13, 2009

Value in Hurco

The Fool briefly mentions Hurco in one of their articles this morning. They note that the company has $4.69 per share in cash. With shares trading around $14.00 right now, that does seem like quite a value.

They also disclose at the end of the article that the Fool owns shares of the company.

April 8, 2009

A Buying Opportunity for Celgene

TheStockAdvisors note that the recent pull back in shares of Celgene make for a good buying opportunity. They say that despite lowering revenue guidance, Celgene is still a "great growth story."

To contrast, Zacks recently lowered the rating on the stock to a Hold with a $45 price target. 52 week low is $36. If you believe in the growth story, now would be a good time to get in.

April 6, 2009

$22 Price Target on ISIS Pharmaceutical

Zacks has a $22 price target on ISIS pharmaceutical this morning. They call one of their products, Mipomersen, "one of the largest potential blockbuster drugs to come to market in the next few years."

April 2, 2009

Long Visa

There is a good article on Seeking Alpha this morning that makes a good case for being long in shares of Visa. In summary, Visa and Mastercard are the only two credit card companies that do not assume any credit risk of their customers; they simply charge a fee for the use of their network.

The author argues that Visa has a larger market share, better immunity from litigation and better prospects for growth.